BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Dr. Dean Regier is an active member of POG’s management committee and since 2015, has worked closely with POG’s clinical and genetics leaders to develop a framework for assessing the early-stage value of WGTA. This framework involves the application of quasi-experimental matching methods alongside analyses of population-based linked administrative health data. Using a mixed methods approach, Dr. Regier’s CCR research lab PACER is estimating the clinical effectiveness and cost-effectiveness of WGTA compared to standard care with a view to support POG program optimization. By engaging key stakeholders,PACER is also generating estimates of preference-based value and predicting future uptake of WGTA to guide advanced cancer care.

Back to top